{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:59:36Z","timestamp":1782262776105,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejca.2022.12.002","type":"journal-article","created":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T23:41:42Z","timestamp":1670802102000},"page":"146-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-2580","authenticated-orcid":false,"given":"Laura D.","family":"Locati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-844X","authenticated-orcid":false,"given":"Elena","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-8219","authenticated-orcid":false,"given":"Marek","family":"Dedecjus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ward","family":"Sents","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9603-0460","authenticated-orcid":false,"given":"Romana","family":"Netea-Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejca.2022.12.002_bib1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.12.002_bib2","first-page":"5888","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ejca.2022.12.002_bib3","article-title":"Age influences the prognosis of anaplastic thyroid cancer patients","volume":"12","author":"Kong","year":"2021","journal-title":"Front Endocrinol [Internet]"},{"issue":"9","key":"10.1016\/j.ejca.2022.12.002_bib4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.002_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nic.2021.04.005","article-title":"Management of anaplastic and recurrent differentiated thyroid cancer: indications for surgical resection, molecular testing, and systemic therapy","volume":"31","author":"Cabanillas","year":"2021","journal-title":"Neuroimaging Clin N Am"},{"issue":"10","key":"10.1016\/j.ejca.2022.12.002_bib6","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"issue":"13","key":"10.1016\/j.ejca.2022.12.002_bib7","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.002_bib8","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.002_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.002_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.002_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","article-title":"Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer","volume":"64","author":"Cantara","year":"2019","journal-title":"Endocrine"},{"issue":"23","key":"10.1016\/j.ejca.2022.12.002_bib12","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2022.12.002_bib13","series-title":"Paris: Annals of Oncology (2022)","article-title":"1646MO - Phase II ATLEP trial: final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma","author":"Dierks","year":"2022"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.12.002_bib14","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1200\/JCO.2020.38.15_suppl.6514","article-title":"Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC)","volume":"38","author":"Cabanillas","year":"2020","journal-title":"JCO"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.12.002_bib15","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","article-title":"A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC)","volume":"38","author":"Lorch","year":"2020","journal-title":"JCO"},{"issue":"7","key":"10.1016\/j.ejca.2022.12.002_bib16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of Lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ejca.2022.12.002_bib17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.12.002_bib18","article-title":"A comparison of post-marketing measures imposed by regulatory agencies to confirm the tissue-agnostic approach","volume":"9","author":"Mulder","year":"2022","journal-title":"Front Med (Lausanne)."},{"issue":"7","key":"10.1016\/j.ejca.2022.12.002_bib19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.002_bib20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/cancers12030596","article-title":"VE1 immunohistochemistry improves the limit of genotyping for detecting BRAFV600E mutation in papillary thyroid cancer","volume":"12","author":"Choden","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2022.12.002_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102380","article-title":"Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era","volume":"106","author":"Capdevila","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ejca.2022.12.002_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s41669-020-00249-0","article-title":"Next-generation sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach?","volume":"5","author":"Pruneri","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"10","key":"10.1016\/j.ejca.2022.12.002_bib23","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/gim.2017.247","article-title":"Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature","volume":"20","author":"Schwarze","year":"2018","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.ejca.2022.12.002_bib24","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.12.002_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.929091","article-title":"What is the status of immunotherapy in thyroid neoplasms?","volume":"13","author":"Garcia-Alvarez","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.ejca.2022.12.002_bib26","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S1470-2045(15)00388-5","article-title":"The value of research collaborations and consortia in rare cancers","volume":"17","author":"Blay","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.12.002_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1470-2045(15)00485-4","article-title":"The promise and challenges of rare cancer research","volume":"17","author":"Komatsubara","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:11Z","timestamp":1760733611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922017907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":27,"alternative-id":["S0959804922017907"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}